- Report
- January 2026
- 197 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- June 2025
- 147 Pages
Global
From €4292EUR$4,900USD£3,725GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Drug Pipelines
- April 2025
- 150 Pages
Global
From €1752EUR$2,000USD£1,520GBP
- Report
- August 2022
- 115 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- August 2024
- 233 Pages
Global
From €6963EUR$7,950USD£6,043GBP
- Report
- January 2024
- 395 Pages
Global
From €6569EUR$7,500USD£5,701GBP
- Report
- January 2025
- 135 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Report
- May 2024
- 140 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Report
- January 2025
- 250 Pages
Global
From €4378EUR$4,999USD£3,800GBP
- Report
- November 2023
- 139 Pages
Global
From €3897EUR$4,450USD£3,383GBP

Zonisamide is a sulfonamide anticonvulsant drug used to treat epilepsy and other seizure disorders. It is classified as a Central Nervous System (CNS) drug, and is used to reduce the frequency and severity of seizures. Zonisamide is also used to treat bipolar disorder, and is sometimes used as an adjunct to other medications for the treatment of depression. Zonisamide is generally well-tolerated, with few side effects. Common side effects include dizziness, drowsiness, and nausea.
The zonisamide market is a small but growing segment of the CNS drug market. It is used to treat a variety of neurological conditions, and is gaining popularity due to its effectiveness and low side effect profile. Zonisamide is available in both generic and branded forms, and is sold in both oral and injectable forms.
Some companies in the zonisamide market include Sun Pharmaceuticals, Teva Pharmaceuticals, Mylan Pharmaceuticals, and Dr. Reddy's Laboratories. Show Less Read more